-
March Market Madness: Johnson & Johnson (JNJ)
Friday, March 18, 2011 - 11:01am | 274As we mentioned earlier, this month we are going to be looking at the stocks that make up the DJIA. . Next up Johnson & Johnson (JNJ). These days, even the mightiest are falling. When the sellers take hold of the action, this is what happens to a stock's chart. J&J is another nice income...
-
Hearing Late-Night Rumors Of Buyout By GlaxoSmithKline For Human Genome Sciences (GSK, HGSI)
Friday, March 18, 2011 - 9:42am | 79The Telegraph mentioned that GlaxoSmithKline (NYSE: GSK) might be interested in buying Human Genome Sciences (NASDAQ: HGSI). The story mentioned Glaxo's synergistic interest in Benlysta. The report, published late last night, can be found here.
-
CPEX Pharmaceuticals Affirms Recommendation That Stockholders Vote for Merger Agreement With FCB
Friday, March 18, 2011 - 9:37am | 57CPEX Pharmaceuticals, Inc. (NASDAQ: CPEX) today announced that its Board of Directors has completed its review of the unsolicited, non-binding letter received from Mangrove Partners on March 16, 2011 revising the terms of the potential alternative transaction involving a recapitalization of CPEX...
-
Hapoalim Securities Reports On AMRN MARINE Trial
Friday, March 18, 2011 - 9:26am | 86Hapoalim Securities has reported that Amarin Corporation's (NASDAQ: AMRN) 12 week Marine trial was positive. According to the report, “Amarin plans to submit an NDA for AMR101 to the FDA in 3Q11 for the indication studied in the MARINE trial (very high triglycerides) regardless of the outcome from...
-
Hapoalim Securities Reiterates Buy Rating on Amarin Corporation (AMRN)
Friday, March 18, 2011 - 9:24am | 216Hapoalim Securities is out with a research report this morning, where it reiterates its Buy rating on Amarin Corporation (NASDAQ: AMRN); it has a $12.00 price target on the stock. The HS analysts cited the company's recent positive MARINE trial, which was a 12-week pivotal study to evaluate the...
-
Piper Jaffray: JNJ Sales Tracking Slightly Below Expectations
Friday, March 18, 2011 - 9:10am | 181Piper Jaffray reports that its analysis of IMS scrips through February indicate that Johnson & Johnson (NYSE: JNJ) US pharma sales are tracking slightly below expectations. “The company's recently launched products continue to perform well in terms of scrips and pricing, however this is more...
-
Committee for Medicinal Products for Human Use (CHMP) Issues Positive Opinion for New Contraception Offering
Friday, March 18, 2011 - 8:43am | 116Teva Pharmaceuticals Europe BV, (NASDAQ: TEVA) and MSD (NYSE: MRK) today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion for NOMAC-E2 an investigational monophasic combined oral contraceptive tablet indicated for the use...
-
Teva Receives Positive Opinion for NOMAC/E2 from the European Committee for Medicinal Products
Friday, March 18, 2011 - 8:36am | 93Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion for NOMAC-E2, an investigational contraceptive pill combining 1.5 mg of 17-beta-estradiol with 2.5 mg of...
-
Benzinga's Top Downgrades (AN, CDCS, AUXL, AEO)
Friday, March 18, 2011 - 8:21am | 147AutoNation Inc (NYSE: AN) was downgraded by Credit Suisse from "outperform" to "neutral." AN's shares closed at $33.17 yesterday. AutoNation's trailing-twelve-month profit margin is 1.82%. Macquarie downgraded CDC Software Corporation (NASDAQ: CDCS) from “outperform” to “neutral.” CDCS' stock...
-
Lilly and Avid Receive Complete Response Letter from FDA for Amyvid
Friday, March 18, 2011 - 7:47am | 76Eli Lilly and Company (NYSE: LLY) and its wholly owned subsidiary, Avid Radiopharmaceuticals, Inc., have received a complete response letter from the U.S. Food and Drug Administration (FDA) for their New Drug Application (NDA) for Amyvid, a Positron Emission Tomography (PET) imaging agent under...
-
Jefferies Leaves Warner Chilcott Buy Rating, $29 PT Unchanged (WCRX)
Friday, March 18, 2011 - 7:46am | 87Jefferies left its Warner Chilcott (NASDAQ: WCRX) Buy rating and $29 price target unchanged in a research report published today. In the report, Jefferies states, "Warner Chilcott was successful in refinancing its outstanding term loans. The company issued $3 billion in new debt at a savings of...
-
Jefferies Has Buy Rating On Amarin Corporation (AMRN)
Friday, March 18, 2011 - 7:43am | 303Jefferies & Co. has a Buy rating and a $12 price target on shares of Amarin Corporation (NASDAQ: AMRN). In a note to clients, Jefferies writes, "Last Patient Visit Completed for ANCHOR - Top-Line Data Expected in 2Q. As a reminder, the Phase 3 ANCHOR study focuses on 702 patients with mixed...
-
Jefferies Comments On Eli Lilly Strattera Appeal
Friday, March 18, 2011 - 7:42am | 171In a report published by Jefferies, Eli Lilly's (NYSE: LLY) Strattera appeal could be an uphill task. Jefferies said that its analysis of the legal issues surrounding the Strattera US patent challenge appeal hearing suggests that the lower court's invalidity ruling is unlikely to be overturned,...
-
A Peek Into The Market Before The Trading Starts
Friday, March 18, 2011 - 7:37am | 488Pre-open moversUS stock futures are higher this morning, as finance ministers and central bankers from the G-7 nations decided to intervene in currency markets to support Japan in curbing the Japanese currency's rise after strong earthquake and tsunami. Futures for the Dow Jones Industrial Average...
-
Morgan Stanley Equal Weight On Auxilium Pharmaceuticals (AUXL)
Friday, March 18, 2011 - 7:18am | 159Morgan Stanley has an Equal Weight rating and a $26 price target on shares of Auxilium Pharmaceuticals (NASDAQ: AUXL). In a note to investors, Morgan Stanley writes, "We are assuming coverage ofAuxilium, a co. focused on urologic and collagen-based diseases, with an EW rating and a $26 PT. Our...